In a regulatory filing, Avidity Biosciences (RNA) president and CEO Sarah Boyce disclosed the sale of 31,855 common shares of the company on December 18 at a price of $32.66 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Jefferies healthcare analyst holds an analyst/industry conference call
- 3 Best Stocks to Buy Now, 12/13/2024, According to Top Analysts
- Avidity Biosciences initiated with an Outperform at RBC Capital
- Dyne Therapeutics initiated with an Outperform at RBC Capital
- Biotech Alert: Searches spiking for these stocks today